Idefirix (Imlifidase)

Imlifidase is an IgG‑degrading enzyme that cleaves human IgG at the lower hinge region, separating the molecule into F(ab')2 and Fc fragments. This action swiftly eliminates donor‑specific antibodies, lowering immunologic risk and facilitating transplantation.

The dosing regimen for Idefirix is determined by the treating physician based on the patient’s clinical status, antibody levels, and transplant protocol. No fixed public dosing schedule is provided; the prescriber sets the appropriate dose.

Safety data for Idefirix in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a specialist.

To order Idefirix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

The primary alternatives for antibody‑mediated desensitization include plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab. Idefirix offers a rapid, single‑dose reduction of IgG antibodies, whereas the alternatives often require multiple sessions over several weeks and may have broader immunosuppressive effects.

Idefirix must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport is essential to preserve product potency.

Idefirix is administered as an intravenous infusion under the supervision of a transplant specialist. The infusion is typically given over a short period, with vital signs monitored before, during, and after the procedure to detect any infusion‑related reactions.

Serious risks include anaphylaxis, serum‑sickness‑like reactions, and opportunistic infections due to the temporary loss of IgG‑mediated immunity. Patients should be observed closely during infusion and monitored for signs of severe allergic response or infection in the days following treatment.

Idefirix is contraindicated in patients with known hypersensitivity to Imlifidase or any component of the formulation, and in individuals who have received live vaccines within four weeks prior to treatment. Caution is also advised for patients with uncontrolled infections or severe uncontrolled comorbidities.